High-density lipoprotein cholesterol and prognosis after myocardial infarction.
The Coronary Drug Project was a randomized, placebo-controlled trial of lipid-influencing drugs in men who had recovered from one or more documented myocardial infarctions. Determinations of high-density lipoprotein (HDL) cholesterol were made at baseline in a group of 354 men randomized to the placebo group. Five-year mortality was highest (33.0%) in men with baseline serum HDL cholesterol levels of less than 35 mg/dl; it was 15.9%, 17.7%, and 21.8% in men with levels of 35--39, 40--44, and greater than or equal to 45 mg/dl, respectively (for the linear inverse relationship between HDL cholesterol and 5-year mortality, p = 0.029). Adjustment for 40 baseline variables had a minimal effect on this relationship (p = 0.042).
D000328:Adult; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality*; D011379:Prognosis; D012907:Smoking; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014481:United States
D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D014280:Triglycerides; D002784:Cholesterol